Investor Presentation Q1 2023

102 Investor presentation First three months of 2023 Growth momentum has increased driven by demographics and utilisation of full product portfolio International Operations is diverse and covers 190 markets Historic growth has been in the range of 5-10% >487m live with diabetes 16% 30% 16 12 >600m live with obesity 8 5% 4 IO's share of revenue FY 2022 اااس 20% 10% 0 0% 2015 2022 Feb 2020 NAO 51% 49% ΙΟ Growth rate range NAO: North America Operations; IO: International Operations; Share of Growth not depicted due to high numbers; FY: Full Year Source (RHS): IQVIA Feb 2023, Value, MAT Growth momentum in IO NN Diabetes market share Market growth NN Diabetes growth Novo NordiskⓇ 27% 18% 13% Feb 2023

View entire presentation